Daiichi Sankyo Company, Limited: Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen

Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca's trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1) Daiichi

Related Keywords

United States ,Japan ,America ,Masashi Kawase ,Daiichi Sankyo ,Daiichi Sankyo Europe Gmb ,Trastuzumab Deruxtecan ,Plexxikon Inc ,Daiichi Sankyo Company ,Oncology Development ,Daiichi Sankyo Inc ,Trastuzumab Deruxtecan Clinical Development Program ,Nasdaq ,Sustainable Development Of Society ,Daiichi Sankyo Co Ltd ,Astrazeneca ,Innovative Global Healthcare Company ,European Medicines Agency ,European Society For Medical Oncology ,Committee For Medicinal Products Human Use ,Sankyo Company ,Medicinal Products ,Human Use ,Medical Oncology ,Gilles Gallant ,Senior Vice President ,Global Head ,North America ,New Drug Application ,Trastuzumab Deruxtecan Clinical Development ,Clinical Cancer Advances ,Molecular Profiling Driving Progress ,Breakthrough Therapy Designation ,Global Healthcare Company Contributing ,Sustainable Development ,Pathol Transl Med ,Cancer Res ,Sankyo Europe Gmbh ,Daiichi ,Sankyo ,Company ,Imited ,Rastuzumab ,Eruxtecan ,Type ,Variation ,Application ,Validated ,Patients ,Ther2 ,Positive ,Metastatic ,Breast ,Dancer ,Reated ,Rior ,Anti ,Ased ,Regimen ,